Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-CD22 CAR T cells |
Synonyms | |
Therapy Description |
Anti-CD22 CAR T cells are T-cells that have been engineered to express a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in enhanced anti-tumor immune response against CD22-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-CD22 CAR T cells | CD22 CAR-T|anti-CD22 CAR-expressing T lymphocytes | CD22 Immune Cell Therapy 15 | Anti-CD22 CAR T cells are T-cells that have been engineered to express a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in enhanced anti-tumor immune response against CD22-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04088890 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT06340737 | Phase I | Anti-CD22 CAR T cells | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | Recruiting | USA | 0 |
NCT02315612 | Phase I | Anti-CD22 CAR T cells | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | Completed | USA | 0 |
NCT04088864 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT06408194 | Phase I | Tisagenlecleucel Anti-CD22 CAR T cells | Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | Recruiting | USA | 0 |
NCT04815356 | Phase I | Anti-CD22 CAR T cells | Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | Recruiting | USA | 0 |
NCT02650414 | Phase I | Anti-CD22 CAR T cells | CD22 Redirected Autologous T Cells for ALL | Recruiting | USA | 0 |